Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ Divests Arimidex And Casodex Rights To Juvisé

Banks Upfront Payment Of $181m

Executive Summary

Selling off the two cancer drugs to the French firm is the latest example of AstraZeneca's strategy of reducing its portfolio of mature assets to boost its R&D budget.

You may also be interested in...



AZ Gets IBD Drug Back From Allergan

Allergan is selling its Crohn’s disease and ulcerative colitis drug brazikumab back to AstraZeneca to satisfy regulators ahead of its link-up with AbbVie, essentially giving the asset to the UK major for free.

Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance

Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.

Anger Over Access To AstraZeneca's Evusheld Peaks In UK

News that the UK government will not procur any doses of AstraZeneca’s Evusheld for the prevention of COVID-19 infections in immunocompromised people has been greeted with dismay and the move will hurt the combo's already-limited sales growth.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel